Prevention and management of chronic kidney disease in type 2 diabetes

Nephrology

Volumn 15, Issue SUPPL. 1, 2010, Pages

  Chadban, S ^a   Howell, M ^a   Twigg, S ^a   Thomas, M ^a   Jerums, G ^a   Cass, A ^a   Campbell, D ^a   Nicholls, K ^a   Tong, A ^a   Mangos, G ^a   Stack, A ^a   MacIsaac, R J ^a   Girgis, S ^a   Colagiuri, R ^a   Colagiuri, S ^a   Craig, J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FENOFIBRATE; GLIBENCLAMIDE; GLICLAZIDE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; METFORMIN; MIGLITOL; NISOLDIPINE; PERINDOPRIL; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; SULODEXIDE; TRANDOLAPRIL; UNINDEXED DRUG; VERAPAMIL;

ALBUMINURIA; ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; REVIEW; RISK FACTOR; SMOKING CESSATION; SODIUM RESTRICTION; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DIET; GLUCOSE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIET; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING CESSATION;

EID: 77950475233     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01240.x     Document Type: Review

References (164)

1. Retnakaran R, Cull CA, Thorne KI et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006 55 : 1832 1839.
2. Hanai K, Babazono T, Iwamoto Y. Renal manifestations of metabolic syndrome in type 2 diabetes. Diabetes. Res. Clin. Prac. 2008 79 : 318 324.
3. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983 32 (Suppl 2 64 78.
4. Newman DJ, Mattock MB, Dawnay AB et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health. Technology. Assessment. 2005 9 : iii vi. xiii 163.
5. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann. Intern. Med. 1996 124 : 90 6.
6. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 352 : 837 853.
7. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes. Res. Clin. Prac. 1995 28 : 103 117.
8. UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998 317 : 703 713.
9. Tapp RJ, Shaw JE, Zimmet PZ et al. Albuminuria is evident in the early stages of diabetes onset: Results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am. J. Kid. Dis. 2004 44 : 792 798.
10. Morioka T, Emoto M, Tabata T et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes. Care. 2001 24 : 909 913.
11. Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009 119 : 351 357.
12. Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: Implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am. J. Cardiol. 1998 82 : 9R 14R.
13. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes. Care. 1998 21 : 597 603.
14. Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann. Intern. Med. 1993 118 : 577 581.
15. Ravid M, Lang R, Rachmani R et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch. Intern. Med. 1996 156 : 286 289.
16. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane. Database. Syst. Rev. 2005 4 : CD004136.
17. Strippoli GF, Bonifati C, Craig M et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane. Database. Syst. Rev. 2006 4 : CD006257.
18. The HOPE Study Group. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000 355 : 253 259.
19. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Eng. J. Med. 2001 345 : 861 869.
20. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Eng. J. Med. 2001 345 : 851 860.
21. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas. Diabetologia. 1999 42 : 263 285.
22. Chan JC, Cockram CS, Nicholls MG et al. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis. BMJ. 1992 305 : 981 985.
23. Ferder L, Daccordi H, Martello M et al. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension. 1992 19 : 237 242.
24. Slataper R, Vicknair N, Sadler R et al. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch. Intern. Med. 1993 153 : 973 980.
25. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes. Care. 1997 20 : 1576 1581.
26. Bruno G, Cavallo-Perin P, Bargero G et al. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 1996 125 : 653 657.
27. Mattock MB, Morrish NJ, Viberti G et al. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992 41 : 736.
28. Nielsen S, Schmitz O, Moller N et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 1993 36 : 1079 1086.
29. Lahdenpera S, Syvanne M, Kahri J et al. Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: Importance of serum triglycerides. Diabetologia. 1996 39 : 453 461.
30. Groop L, Ekstrand A, Forsblom C et al. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1993 36 : 642 647.
31. Jenkins AJ, Steele JS, Janus ED et al. Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 1992 35 : 1055 1059.
32. Jerums G, Allen TJ, Tsalamandris C et al. Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients. Diabetologia. 1993 36 : 1037 1044.
33. Keane WF, Kasiske BL, O'Donnell MP. Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am. J. Nephrol. 1988 8 : 261 271.
34. Pyorala K, Pedersen TR, Kjekshus J et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study. Diabetes. Care. 1997 20 : 614 620.
35. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Eng. J. Med. 1996 335 : 1001 1009.
36. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Eng. J. Med. 1995 333 : 1301 1307.
37. Kannel WB. Cardioprotection and antihypertensive therapy: The key importance of addressing the associated coronary risk factors (the Framingham experience). Am. J. Cardiol. 1996 77 : B6 B11.
38. Stamler J, Vaccaro O, Neaton JD et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes. Care. 1993 16 : 434 444.
39. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N. Eng. J. Med. 1984 311 (2 89 93.
40. Schmitz A, Vaeth M. Microalbuminuria: A major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabetic. Med. 1988 5 : 126 134.
41. Parving HH. Renoprotection in diabetes: Genetic and non-genetic risk factors and treatment. Diabetologia. 1998 41 : 745 759.
42. Smulders YM, van Eeden AE, Stehouwer CD et al. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus Euro. J. Clin. Invest. 1997 27 : 997 1002.
43. National Heart Foundation of Australia. Lipid Management Guidelines. Med. J. Aust. 2001 9 Suppl S57 S88.
44. Costa J, Borges M, David C et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Meta-analysis of randomised controlled trials. BMJ. 2006 332 : 1115 1124.
45. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. V 5.0.0. The Cochrane Collaboration 2008 Cited April 2008.] Available from URL: http://www.cochrane-handbook.org
46. Levin SR, Coburn JW, Abraira C et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Diabetes. Care. 2000 23 : 1478 1485.
47. Shichiri M, Kishikawa H, Ohkubo Y et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes. Care. 2000 23 (2 Suppl B21 B29.
48. Richter B, Bandeira-Echtler E, Bergerhoff K et al. Pioglitazone for type 2 diabetes mellitus. Cochrane. Database. Syst. Rev. 2006 4.
49. Hanefeld M, Brunetti P, Schernthaner GH et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes. Care. 2004 27 : 141 147. (Pubitemid 38196723)
50. Matthews DR, Charbonnel BH, Hanefeld M et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: A randomized, comparative study. Diabetes/Metabolism. Res. Rev. 2005 21 : 167 174. (Pubitemid 40467663)
51. Schernthaner G, Matthews DR, Charbonnel B et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A double-blind, randomized trial. J. Clin. Endocrinol. Metabol. 2004 89 : 6068 6076.
52. Richter B, Bandeira-Echtler E, Bergerhoff K et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane. Database. Syst. Rev. 2007 3.
53. Lebovitz HE, Dole JF, Patwardhan R et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J. Clin. Endocrinol. Metabol. 2001 86 : 280 288.
54. Bakris G, Viberti G, Weston WM et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J. Hum. Hypertens. 2003 17 : 7 12.
55. Saenz A, Fernandez-Esteban I, Mataix A et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane. Database. Syst. Rev. 2005 3.
56. Amador-Licona N, Guizar-Mendoza J, Vargas E et al. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Arch. Med. Res. 2000 31 : 571 575.
57. De Jager J, Kooy A, Lehert P et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: A randomized, placebo-controlled trial. J. Intern. Med. 2005 257 : 100 109.
58. ADVANCE Collaborative Group, Patel A, MacMahon S et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Eng. J. Med. 2008 358 : 2560 2572.
59. Davidson JA, McMorn SO, Waterhouse BR et al. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Clin. Ther. 2007 29 : 1900 1914.
60. Johnston PS, Feig PU, Coniff RF et al. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes. Care. 1998 2 : 409 415.
61. Johnston PS, Feig PU, Coniff RF et al. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Diabetes. Care. 1998 21 : 416 422.
62. Gambaro G, Kinalska I, Oksa A et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial. J. Am. Soc. Nephrol. 2002 13 : 1615 1625.
63. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Eng. J. Med. 2003 348 : 383 393. (Pubitemid 36159355)
64. Kaiser T, Florack C, Stephan U et al. Should BP targets be lower in diabetic patients with microalbuminuria or nephropathy: A systematic review of randomised controlled trials (Provisional record). Br. J. Diabetes. Vasc. Dis. 2003 3 : 278 281.
65. UKPDS. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998 317 : 713 720.
66. Ravid M, Brosh D, Ravid-Safran D et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch. Intern. Med. 1998 158 : 998 1004.
67. Patel A, ADVANCE Collaborative Group, MacMahon S et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007 370 : 829 840.
68. de Galan B, Perkovic V, Ninomiya T et al. Lowering blood pressure reduces renal events in Type 2 diabetes. J. Am. Soc. Nephrol. 2009 20 : 883 892.
69. Sano T, Hotta N, Kawamura T et al. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: Results of a 4-year, prospective, randomized study. Diabetic. Medicine. 1996 13 : 120 124.
70. Schrier RW, Estacio RO, Esler A et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney. Int. 2002 61 : 1086 1097.
71. Lebovitz HE, Wiegmann TB, Cnaan A et al. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney. Int. 1994 45 : S150 S55.
72. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Eng. J. Med. 2001 345 : 870 878.
73. Estacio RO, Jeffers BW, Gifford N et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes. Care. 2000 23 (Suppl 2 B54 B64.
74. Agardh CD, Garcia-Puig J, Charbonnel B et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J. Hum. Hypertens. 1996 10 : 185 192.
75. Lacourciere Y, Nadeau A, Poirier L et al. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension. 1993 21 : 786 794.
76. Chan JC, Ko GT, Leung DH et al. Long-term effects of angiotensin- converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney. Int. 2000 57 : 590 600.
77. Jennings DL, Kalus JS, Coleman CI et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: A meta-analysis. Diabetic. Med. 2007 24 : 486 493.
78. Hamilton RA, Kane MP, Demers J. Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: A meta-analysis. Pharmacotherapy. 2003 23 : 909 915.
79. Yasuda G, Ando D, Hirawa N et al. Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. Diabetes. Care. 2005 28 : 1862 1868. (Pubitemid 41060955)
80. Jerums G, Allen TJ, Campbell DJ et al. Melbourne Diabetic Nephropathy Study Group. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. Diabetic. Med. 2004 21 : 1192 1199.
81. Marre M, Lievre M, Chatellier G et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: Randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004 328.
82. Baba S, MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes. Res. Clin. Prac. 2001 54 : 191 201.
83. Fogari R, Zoppi A, Corradi L et al. Long-term effects of amlodipine versus fosinopril on microalbuminuria in elderly hypertensive patients with type 2 diabetes mellitus. Curr. Ther. Res. Clin. Exp. 2000 61 : 163 173.
84. Lacourciere Y, Belanger A, Godin C et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney. Int. 2000 58 : 762 769.
85. Estacio RO, Coll JR, Tran ZV et al. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am. J. Hypertens. 2006 19 : 1241 1248.
86. Galle J, Schwedhelm E, Pinnetti S et al. Antiproteinuric effects of angiotensin receptor blockers: Telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol. Dial. Transplant. 2008 23 : 3174 3183.
87. Hollenberg NK, Parving HH, Viberti G et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J. Hypertens. 2007 25 : 1921 1926.
88. Shiga Microalbuminuria Reduction Trial (SMART) Group, Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A. Reduction of microalbuminuria in patients with type 2 diabetes: The Shiga Microalbuminuria Reduction Trial (SMART). Diabetes. Care. 2007 30 : 1581 1583. (Pubitemid 46871176)
89. Tan KC, Chow WS, Ai VH et al. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes. Metabol. Res. Rev. 2002 18 : 71 6.
90. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation. 2002 106 : 672 678.
91. Ruggenenti P, Gambara V, Perna A et al. The nephropathy of non-insulin-dependent diabetes: Predictors of outcome relative to diverse patterns of renal injury. J. Am. Soc. Nephrol. 1998 9 : 2336 2343.
92. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: The BENEDICT study. J. Am. Soc. Nephrol. 2006 17 : S90 S97.
93. Schram MT, van Ittersum FJ, Spoelstra-de Man A et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: Effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J. Hum. Hypertens. 2005 19 : 429 437.
94. Rosei EA, Rizzoni D, Muiesan ML et al. CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J. Hypertens. 2005 23 : 435 444.
95. Bakris GL, Fonseca V, Katholi RE et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005 46 : 1309 1315.
96. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Eng. J. Med. 2004 351 : 1952 1961.
97. ONTARGET. Ramipril, or both in patients at high risk for vascular events. N. Eng. J. Med. 2008 358 : 1547 1559.
98. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008 372 : 547 553.
99. Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Eng. J. Med. 2008 358 : 2433 2446.
100. Muirhead N, Feagan BF, Mahon J et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: A placebo-controlled trial. Curr. Ther. Res. Clin. Exp. 1999 60 : 650 660. (Pubitemid 30036150)
101. Ravid M, Brosh D, Levi Z et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 1998 128 : 982 988.
102. Sano T, Kawamura T, Matsumae H et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes. Care. 1994 17 : 420 424.
103. Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am. J. Hypertens. 1995 8 : 876 883.
104. Sandhu S, Wiebe N, Fried L et al. Statins for improving renal outcomes: A meta-analysis. J. Am. Soc. Nephrol. 2006 17 : 2006 2016.
105. Keating GM, Croom KF. Fenofibrate: A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007 67 : 121 153.
106. Strippoli G, Navaneethan S, Johnson D et al. Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008 336 : 645 651.
107. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney. Int. 2001 59 : 260 269.
108. The Heart Protection Study. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet. 2003 361 : 2005 2016.
109. Athyros VG, Mikhailidis DP, Papageorgiou AA et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J. Clin. Pathol. 2004 57 : 728 734.
110. Koren MJ. Statin use in a 'real-world' clinical setting: Aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial. Am. J. Med. 2005 118 (Suppl 12A 16 21.
111. Sorof J, Berne C, Siewert-Delle A et al. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes. Res. Clin. Prac. 2006 72 : 81 7.
112. Nakamura T, Ushiyama C, Hirokawa K et al. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am. J. Nephrol. 2001 21 : 449 454. (Pubitemid 34088200)
113. Ansquer JC, Foucher C, Rattier S et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney. Dis. 2005 45 : 485 493.
114. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet. 2005 366 : 1849 1861.
115. Radermecker RP, Scheen AJ. Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes. Revue. Medicale. Liege. 2005 60 : 957 961.
116. Nagai T, Tomizawa T, Nakajima K et al. Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J. Atherosclerosis. Thrombosis. 2000 7 : 91 6.
117. Endo K, Miyashita Y, Sasaki H et al. Probucol delays progression of diabetic nephropathy. Diabetes. Res. Clin. Prac. 2006 71 : 156 163.
118. Cardenas C, Bordiu E, Bagazgoitia J et al. Polyunsaturated fatty acid consumption may play a role in the onset and regression of microalbuminuria in well-controlled type 1 and type 2 diabetic people: A 7-year, prospective, population-based, observational multicenter study. Diabetes. Care. 2004 27 : 1454 1457.
119. Shemesh O, Golbetz H, Kriss JP et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney. Int. 1985 28 : 830 838.
120. Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane. Database. Syst. Rev. 2007 4.
121. Dussol B, Iovanna C, Raccah D et al. A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy. J. Renal. Nutr. 2005 15 : 398 406.
122. Suckling RJ, He FJ, MacGregor GA. Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane. Database. Syst. Rev. Protoc. 2007 4 : CD006763.
123. Muhlhauser I. Cigarette smoking and diabetes: An update. Diabetic. Med. 1994 11 : 336 343.
124. Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ. 1993 306 : 1313 1318.
125. Forsblom CM, Sane T, Groop PH et al. Risk factors for mortality in Type II (non-insulin-dependent) diabetes: Evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia. 1998 41 : 1253 1262.
126. Gambaro G, Bax G, Fusaro M et al. Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. Diabetes. Nutr. Metabol. Clin. Exp. 2001 14 : 337 342.
127. Smulders YM, Rakic M, Stehouwer CD et al. Determinants of progression of microalbuminuria in patients with NIDDM. A prospective study. Diabetes. Care. 1997 6 : 999 1005.
128. Chuahirun T, Wesson DE. Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition. Am. J. Kidney. Dis. 2002 39 : 376 382.
129. Chuahirun T, Simoni J, Hudson C et al. Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am. J. Med. Sci. 2004 327 : 57 67.
130. Chuahirun T, Khanna A, Kimball K et al. Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes. Am. J. Kidney. Dis. 2003 4 : 3 21.
131. Cederholm J, Eliasson B, Nilsson PM et al. Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. Diabetes. Res. Clin. Prac. 2005 67 : 258 266.
132. Biarnes J, Masana L, Morales C et al. Factors influencing incipient diabetic nephropathy: ESODIAH study. Medicina. Clinica. 2005 125 : 401 404.
133. Braatvedt GD, Rosie B, Bagg W et al. Current and former smoking increases mortality in patients on peritoneal dialysis. NZ. Med. J. 2006 119.
134. Nakamura T, Ushiyama C, Osada S et al. Combination therapy of trandolapril and candesartan cilexetil reduces microalbuminuria and urinary endothelin-1 excretion in patients with type 2 diabetes. Clin. Exp. Nephrol. 2002 6 : 135 139.
135. Nishimura M, Sasaki T, Ohishi A et al. Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy. Clin. Nephrol. 2001 56 : 96 103.
136. Barnard ND, Cohen J, Jenkins DJ et al. A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes. Care. 2006 29 : 1777 1783.
137. Nicholson AS, Sklar M, Barnard ND et al. Toward improved management of NIDDM: A randomized, controlled, pilot intervention using a lowfat, vegetarian diet. Prev. Med. 1994 29 : 87 91.
138. Nielsen S, Hermansen K, Rasmussen OW et al. Urinary albumin excretion rate and 24-h ambulatory blood pressure in NIDDM with microalbuminuria: Effects of a monounsaturated-enriched diet. Diabetologia. 1995 38 : 1069 1075.
139. Shimizu H, Ohtani K, Tanaka Y et al. Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. Diabetes. Res. Clin. Prac. 1995 28 : 35 40.
140. Barsotti G, Cupisti A, Barsotti M et al. Dietary treatment of diabetic nephropathy with chronic renal failure. Nephrol. Dial. Transplant. 1998 13 (Suppl 8 49 52.
141. de mello VD, Zelmanovitz T, Perassolo MS et al. Withdrawal of red meat from the usual diet reduces albuminuria and improves serum fatty acid profile in type 2 diabetes patients with macroalbuminuria. Am. J. Clin. Nutr. 2006 83 : 1032 1038.
142. Gross JL, Zelmanovitz T, Moulin CC et al. Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: A randomized crossover trial. Diabetes. Care. 2002 25 : 645 651.
143. Meloni C, Tatangelo P, Cipriani S et al. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. J. Renal. Nutr. 2004 14 : 208 213.
144. Pijls LT, de Vries H, Donker AJ et al. The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: A randomized trial. Nephrol. Dial. Transplant. 1999 14 : 1445 1453.
145. Pijls LT, de Vries H, van Eijk JT et al. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: A randomized trial. Euro. J. Clin. Nutr. 2002 56 : 1200 1207.
146. Pomerleau J, Verdy M, Garrel DR et al. Effect of protein intake on glycaemic control and renal function in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1993 36 : 829 834.
147. Teixeira SR, Tappenden KA, Carson L et al. Isolated soy protein consumption reduces urinary albumin excretion and improves the serum lipid profile in men with type 2 diabetes mellitus and nephropathy. J. Nutrition. 2004 134 : 1874 1880.
148. Wheeler ML, Fineberg SE, Fineberg NS et al. Animal versus plant protein meals in individuals with type 2 diabetes and microalbuminuria: Effects on renal, glycemic, and lipid parameters. Diabetes. Care. 2002 25 : 1277 1282.
149. Houlihan C, Allen T, Hovey A et al. A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan. Nephrology. 2000 5.
150. Houlihan CA, Akdeniz A, Tsalamandris C et al. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: Effects of angiotensin receptor blockade and sodium restriction. Diabetes. Care. 2002 25 : 1072 1077.
151. Houlihan CA, Allen TJ, Baxter AL et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes. Care. 2002 25 : 663 671.
152. Imanishi M, Yoshioka K, Okumura M et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes. Care. 2001 24 : 111 116.
153. Vedovato M, Lepore G, Coracina A et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: The role of insulin resistance. Diabetologia. 2004 47 : 300 303.
154. Yoshioka K, Imanishi M, Konishi Y et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes. Care. 1998 21 : 482 486.
155. Anan F, Masaki T, Takahashi N et al. Smoking is associated with urinary albumin excretion: An evaluation of premenopausal patients with type 2 diabetes mellitus. Metab. Clin. Exp. 2007 56 : 179 184.
156. Baggio B, Budakovic A, Dalla VM et al. Effects of cigarette smoking on glomerular structure and function in type 2 diabetic patients. J. Am. Soc. Nephrol. 2002 13 : 2730 2736.
157. Corradi L, Zoppi A, Tettamanti F et al. Association between smoking and micro-albuminuria in hypertensive patients with type 2 diabetes mellitus. J. Hypertension. 1993 11 : S190 S91.
158. Dean JD, Matthews SB, Dolben J et al. Cholesterol rich apo B containing lipoproteins and smoking are independently associated with macrovascular disease in normotensive NIDDM patients. Diabetic. Medicine. 1994 11 : 740 747.
159. Gatling W, Mullee MA, Knight C et al. Microalbuminuria in diabetes: Relationships between urinary albumin excretion and diabetes-related variables. Diabetic. Medicine. 1988 5 : 348 351.
160. Ikeda Y, Suehiro T, Takamatsu K et al. Effect of smoking on the prevalence of albuminuria in Japanese men with non-insulin-dependent diabetes mellitus. Diabetes. Res. Clin. Prac. 1997 36 : 57 61.
161. Nilsson PM, Gudbjornsdottir S, Eliasson B et al. Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes - Data from the National Diabetes Register in Sweden. Diab. &. Metab. 2004 30 (3 261 268.
162. Pijls LT, de Vries H, Kriegsman DM et al. Determinants of albuminuria in people with Type 2 diabetes mellitus. Diabetes. Res. Clin. Prac. 2001 52 : 133 143.
163. Savage S, Nagel NJ, Estacio RO et al. Clinical factors associated with urinary albumin excretion in type II diabetes. Am. J. Kidney. Dis. 1995 25 : 836 844.
164. Thomas GN, Tomlinson B, McGhee SM et al. Association of smoking with increasing vascular involvement in type 2 diabetic Chinese patients. Exp. Clin. Endocrinol. Diab. 2006 114 : 301 305.